Summary The Emerging 5 Pharmaceuticals industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2011-15, and forecast to 2020). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Findings - Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging five pharmaceuticals market - Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging five pharmaceuticals market - Leading company profiles reveal details of key pharmaceuticals market players' emerging five operations and financial performance - Add weight to presentations and pitches by understanding the future growth prospects of the emerging five pharmaceuticals market with five year forecasts - Compares data from Brazil, China, India, Mexico and South Africa, alongside individual chapters on each country
Synopsis Essential resource for top-line data and analysis covering the emerging five pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends and leading companies.
Reasons To Buy - What was the size of the emerging five pharmaceuticals market by value in 2015? - What will be the size of the emerging five pharmaceuticals market in 2020? - What factors are affecting the strength of competition in the emerging five pharmaceuticals market? - How has the market performed over the last five years? - Who are the top competitors in the emerging five pharmaceuticals market?
Key Findings - These countries contributed $149.8 billion to the global pharmaceuticals industry in 2015, with a compound annual growth rate (CAGR) of 12.7% between 2007 and 2011. The top 5 emerging countries are expected to reach a value of $235.3 billion in 2020, with a CAGR of 9.4% over the 2015-20 period.
- Within the pharmaceuticals industry, China is the leading country among the top 5 emerging nations, with market revenues of $97.9 billion in 2015. This was followed by India and Brazil with a value of $26.8 and $13.9 billion, respectively.
- China is expected to lead the pharmaceuticals industry in the top five emerging nations, with a value of $145.4 billion in 2020, followed by India and Brazil with expected values of $57.5 and $19.2 billion, respectively.
Our reports have been used by over 10K customers, including:
Erectile Dysfunction (Women’s and Male Health) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction - Drugs in Development, 2021, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape. Erectile...
Thromboembolism (Cardiovascular) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Drugs in Development, 2021, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape. When a blood clot (thrombus)...
Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 184.108.40.206) - Drugs in Development, 2021 Summary According to the recently published report ’Tyrosine Protein Kinase SYK - Drugs in Development, 2021’; Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or...
The Global Pharmaceutical CDMO Market was valued USD 160.12 billion in 2020, and it is expected to reach USD 236.61 billion by 2026, registering a CAGR of 6.5%, during the period of forecast period (2021-2026). The CMO/CDMO service sector is uniquely positioned to address some of the challenges that drug developers are facing amid the COVID-19...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
The global pharmaceutical contract development and manufacturing market is projected to reach USD 146.1 billion by 2025 from USD 100.7 billion in 2020, at a CAGR of 7.7% during the forecast period. Market growth is driven mainly by factors such as rising demand for generics, increasing investments in pharmaceutical R&D, and investments in...
Myasthenia Gravis (Immunology) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Myasthenia Gravis - Drugs in Development, 2021, provides an overview of the Myasthenia Gravis (Immunology) pipeline landscape. Myasthenia gravis is autoimmune...
The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.